109 related articles for article (PubMed ID: 21907090)
1. Genetics of tardive dyskinesia.
Lee HJ; Kang SG
Int Rev Neurobiol; 2011; 98():231-64. PubMed ID: 21907090
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
Cho CH; Lee HJ
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():207-13. PubMed ID: 23123399
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes.
Zai CC; Tiwari AK; Basile V; de Luca V; Müller DJ; Voineskos AN; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Kennedy JL
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):50-6. PubMed ID: 19778569
[TBL] [Abstract][Full Text] [Related]
4. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.
Thelma B; Srivastava V; Tiwari AK
Pharmacogenomics; 2008 Sep; 9(9):1285-306. PubMed ID: 18781856
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
Arranz MJ; de Leon J
Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
[TBL] [Abstract][Full Text] [Related]
6. [The genetics of antipsychotic-related movement disorders].
Bakker PR; van Os J; van Harten PN
Tijdschr Psychiatr; 2015; 57(2):114-9. PubMed ID: 25669949
[TBL] [Abstract][Full Text] [Related]
7. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia.
Greenbaum L; Alkelai A; Rigbi A; Kohn Y; Lerer B
Mov Disord; 2010 Dec; 25(16):2809-17. PubMed ID: 20939080
[TBL] [Abstract][Full Text] [Related]
8. [Genome-wide association analyses for neuroleptic-induced tardive dyskinesia].
Arinami T; Inada T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Aug; 31(4):155-62. PubMed ID: 21941849
[TBL] [Abstract][Full Text] [Related]
9. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T
Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
11. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.
Greenbaum L; Alkelai A; Zozulinsky P; Kohn Y; Lerer B
Pharmacogenomics J; 2012 Dec; 12(6):513-20. PubMed ID: 21808285
[TBL] [Abstract][Full Text] [Related]
12. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients.
Zai CC; Tiwari AK; Basile V; De Luca V; Müller DJ; King N; Voineskos AN; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Kennedy JL
Pharmacogenomics J; 2009 Jun; 9(3):168-74. PubMed ID: 19238168
[TBL] [Abstract][Full Text] [Related]
13. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
Basile VS; Ozdemir V; Masellis M; Meltzer HY; Lieberman JA; Potkin SG; Macciardi FM; Petronis A; Kennedy JL
Mol Psychiatry; 2001 Mar; 6(2):230-4. PubMed ID: 11317228
[TBL] [Abstract][Full Text] [Related]
14. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.
Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Mukit SR; Shriharsh V; Lerer B; Nimagaonkar VL; Thelma BK
Pharmacogenomics J; 2005; 5(1):60-9. PubMed ID: 15505641
[TBL] [Abstract][Full Text] [Related]
15. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.
Segman RH; Heresco-Levy U; Finkel B; Goltser T; Shalem R; Schlafman M; Dorevitch A; Yakir A; Greenberg D; Lerner A; Lerer B
Mol Psychiatry; 2001 Mar; 6(2):225-9. PubMed ID: 11317227
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
Lanning RK; Zai CC; Müller DJ
Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and risk factors for (tardive) dyskinesia.
Tenback DE; van Harten PN
Int Rev Neurobiol; 2011; 98():211-30. PubMed ID: 21907089
[TBL] [Abstract][Full Text] [Related]
18. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
19. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.
de Leon J; Susce MT; Pan RM; Koch WH; Wedlund PJ
J Clin Psychopharmacol; 2005 Oct; 25(5):448-56. PubMed ID: 16160620
[TBL] [Abstract][Full Text] [Related]
20. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia.
Kang SG; Lee HJ; Choi JE; An H; Rhee M; Kim L
Hum Psychopharmacol; 2009 Jan; 24(1):55-60. PubMed ID: 19051221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
